AZACITIDINE
AT148002
Phase 2 small_molecule active
Quick answer
AZACITIDINE for Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease is a Phase 2 program (small_molecule) at ALX ONCOLOGY HOLDINGS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALX ONCOLOGY HOLDINGS INC
- Indication
- Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active